Algorae Pharmaceuticals Limited

As of June 30, 2024, ALGORAE PHARMACEUTICALS LTD. carries a market capitalization of 11.77M, placing it among publicly traded companies globally. Its enterprise value stands at 9.70M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2024, ALGORAE PHARMACEUTICALS LTD. has 1.69B shares outstanding.

These figures are as of June 30, 2024.

As of June 30, 2024, ALGORAE PHARMACEUTICALS LTD. maintains a current ratio of 30.78, meaning it holds 30.8x the short-term assets needed to cover near-term liabilities.

Over the twelve months ended June 30, 2024, ALGORAE PHARMACEUTICALS LTD. posted a negative return on equity (ROE) of -61.85, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -35.74, reflecting losses generated across the asset base.

As of the close on June 29, 2026, ALGORAE PHARMACEUTICALS LTD.'s stock has gained approximately 76.85% over the past 52 weeks. The 50-day moving average sits at 0.01, while the 200-day moving average is 0.01.

These figures cover the twelve months ended June 30, 2024. EBITDA reached -1.47M, while operating income came in at -1.47M.

These figures are as of June 30, 2024. Total book value stands at 2.01M, with working capital of 3.55M providing operational flexibility.

These figures cover the twelve months ended June 30, 2024. Total shareholder yield is negative at -2.97, meaning ALGORAE PHARMACEUTICALS LTD. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

ALGORAE PHARMACEUTICALS LTD.'s most recent stock split took place on March 23, 2023 with a 80:81 split ratio.